Stéphane Roueff

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients

Cécile Couchoud, Florian Bayer, Carole Ayav et al. · Kidney International · 2020 · 150 citations · Full text

Hemodialysis, Medicine, Covid-19 Pandemic +9

Extracellular fluid volume is associated with incident end-stage kidney disease and mortality in patients with chronic kidney disease

Anne‐Laure Faucon, Martin Flamant, Marie Metzger et al. · Kidney International · 2019 · 46 citations · Full text

Glomerulonephritis, Hemodialysis, Urology +9

Sheehan syndrome presenting as early post-partum hyponatraemia

Éric Boulanger, Dominique Pagniez, Stéphane Roueff et al. · Nephrology Dialysis Transplantation · 1999 · 35 citations

Fetal Medicine, Pathology, Gynecology +21